COVID-19 中的血管内皮功能障碍需要立即引起重视：血管内皮在由 SARS-CoV-2 引起的炎症中的新作用。
Endothelial dysfunction in COVID-19 calls for immediate attention: the emerging roles of the endothelium in inflammation caused by SARS-CoV-2.
机构信息
Division of Cardiology, Department of Internal Medicine, and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
出版信息
Front Med. 2021 Aug;15(4):638-643. doi: 10.1007/s11684-021-0831-z. Epub 2021 Mar 21.
Abstract
The COVID-19 pandemic has caused numerous deaths around the world. A growing body of evidence points to the important role of overwhelming inflammatory responses in the pathogenesis of COVID-19 and the effectiveness of anti-inflammation therapy against COVID-19 is emerging. In addition to affecting the lungs, COVID-19 can be a severe systemic inflammatory disease that is related to endothelial dysfunction. We are calling for closer attention to endothelial dysfunction in COVID-19 not only for fully revealing the pathogenic mechanism of COVID-19 but also for properly adjusting the strategy of clinical intervention.
摘要
新型冠状病毒肺炎（COVID-19）大流行在全球范围内导致了大量死亡。越来越多的证据表明，炎症反应过度在 COVID-19 的发病机制中起着重要作用，抗炎治疗对 COVID-19 的有效性正在显现。除了影响肺部之外，COVID-19 还可能是一种严重的全身性炎症性疾病，与内皮功能障碍有关。我们呼吁密切关注 COVID-19 中的内皮功能障碍，这不仅有助于充分揭示 COVID-19 的发病机制，而且有助于正确调整临床干预策略。
相似文献
1
Endothelial dysfunction in COVID-19 calls for immediate attention: the emerging roles of the endothelium in inflammation caused by SARS-CoV-2.COVID-19 中的血管内皮功能障碍需要立即引起重视：血管内皮在由 SARS-CoV-2 引起的炎症中的新作用。
Front Med. 2021 Aug;15(4):638-643. doi: 10.1007/s11684-021-0831-z. Epub 2021 Mar 21.
2
Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.SARS-CoV-2 激活的肥大细胞释放组织胺，增加白细胞介素-1 水平，导致 COVID-19 中的细胞因子风暴和炎症反应。
J Biol Regul Homeost Agents. 2020;34(5):1629-1632. doi: 10.23812/20-2EDIT.
3
IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).白细胞介素-1（IL-1）在 COVID-19 中诱导血栓烷 A2（TxA2）的产生，导致炎症和微血栓形成：白细胞介素-1 受体拮抗剂（IL-1Ra）的抑制作用。
J Biol Regul Homeost Agents. 2020;34(5):1623-1627. doi: 10.23812/20-34-4EDIT-65.
4
Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19-Mechanisms and Therapeutic Targets.新型冠状病毒病中的血管内皮功能障碍、炎症和氧化应激：机制与治疗靶点。
Oxid Med Cell Longev. 2021 Aug 21;2021:8671713. doi: 10.1155/2021/8671713. eCollection 2021.
5
Understanding COVID-19-associated endothelial dysfunction: role of PIEZO1 as a potential therapeutic target.了解 COVID-19 相关的血管内皮功能障碍：PIEZO1 作为潜在治疗靶点的作用。
Front Immunol. 2024 Feb 29;15:1281263. doi: 10.3389/fimmu.2024.1281263. eCollection 2024.
6
Endothelial Dysfunction as a Primary Consequence of SARS-CoV-2 Infection.内皮功能障碍作为 SARS-CoV-2 感染的主要后果。
Adv Exp Med Biol. 2021;1321:33-43. doi: 10.1007/978-3-030-59261-5_3.
7
Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19.维生素 D 缺乏与内皮功能障碍相关：对 COVID-19 患者的影响。
Rev Cardiovasc Med. 2020 Sep 30;21(3):339-344. doi: 10.31083/j.rcm.2020.03.131.
8
Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses.重组 ACE2 表达是 SARS-CoV-2 感染原代人血管内皮细胞并诱导炎症和促凝反应所必需的。
mBio. 2020 Dec 11;11(6):e03185-20. doi: 10.1128/mBio.03185-20.
9
Endothelial inflammation and dysfunction in COVID-19.COVID-19 中的内皮炎症和功能障碍。
Vasa. 2022 Mar;51(2):62-70. doi: 10.1024/0301-1526/a000991. Epub 2022 Feb 16.
10
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.COVID-19 患者的激肽释放酶-激肽系统阻断治疗以预防急性呼吸窘迫综合征。
Elife. 2020 Apr 27;9:e57555. doi: 10.7554/eLife.57555.
引用本文的文献
1
Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trial.波生坦用于 COVID-19 感染高危门诊患者：一项随机、双盲、安慰剂对照试验。
EClinicalMedicine. 2023 Jul 27;62:102117. doi: 10.1016/j.eclinm.2023.102117. eCollection 2023 Aug.
2
COVID-19 in Joint Ageing and Osteoarthritis: Current Status and Perspectives.COVID-19 与老年共病和骨关节炎：现状与展望。
Int J Mol Sci. 2022 Jan 10;23(2):720. doi: 10.3390/ijms23020720.
3
Inflammation at the crossroads of and COVID-19.炎症处于[具体病症]与COVID-19的交叉点。
你提供的原文中“and”前面似乎缺失了具体内容，请补充完整以便我给出更准确的译文。
Future Microbiol. 2022 Jan;17(2):77-80. doi: 10.2217/fmb-2021-0250. Epub 2021 Dec 17.
4
cAMP Compartmentalization in Cerebrovascular Endothelial Cells: New Therapeutic Opportunities in Alzheimer's Disease.脑血管内皮细胞中环磷酸腺苷的区室化：阿尔茨海默病的新治疗机会。
Cells. 2021 Jul 31;10(8):1951. doi: 10.3390/cells10081951.
5
The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction.锌指转录因子 KLF2 可预防 COVID-19 相关的内皮功能障碍。
Signal Transduct Target Ther. 2021 Jul 12;6(1):266. doi: 10.1038/s41392-021-00690-5.
6
ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients.ACE2 下调可能是一种短暂的分子疾病，导致 COVID-19 患者的微循环环境中 RAAS 失调和组织损伤。
Am J Pathol. 2021 Jul;191(7):1154-1164. doi: 10.1016/j.ajpath.2021.04.010. Epub 2021 May 6.
本文引用的文献
1
Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans.人类对轻度与重度 COVID-19 感染免疫的系统生物学评估。
Science. 2020 Sep 4;369(6508):1210-1220. doi: 10.1126/science.abc6261. Epub 2020 Aug 11.
2
Extrapulmonary manifestations of COVID-19.COVID-19 的肺外表现。
Nat Med. 2020 Jul;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3. Epub 2020 Jul 10.
3
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.新型冠状病毒肺炎相关凝血病中的内皮病变：来自一项单中心横断面研究的证据
Lancet Haematol. 2020 Aug;7(8):e575-e582. doi: 10.1016/S2352-3026(20)30216-7. Epub 2020 Jun 30.
4
Dexamethasone for COVID-19? Not so fast.地塞米松治疗 COVID-19？先别急。
J Biol Regul Homeost Agents. 2020;34(3):1241-1243. doi: 10.23812/20-EDITORIAL_1-5.
5
Platelet Transforming Growth Factor-β1 Induces Liver Sinusoidal Endothelial Cells to Secrete Interleukin-6.血小板转化生长因子-β1 诱导肝窦内皮细胞分泌白细胞介素-6。
Cells. 2020 May 25;9(5):1311. doi: 10.3390/cells9051311.
6
COVID-19: the vasculature unleashed.COVID-19：血管失控。
Nat Rev Immunol. 2020 Jul;20(7):389-391. doi: 10.1038/s41577-020-0343-0.
7
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.使用临床级别的可溶性人血管紧张素转化酶 2 抑制工程化人类组织中的 SARS-CoV-2 感染。
Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.
8
Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
9
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.双嘧达莫对重症 COVID-19 患者的潜在治疗作用。
Acta Pharm Sin B. 2020 Jul;10(7):1205-1215. doi: 10.1016/j.apsb.2020.04.008. Epub 2020 Apr 20.
10
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.托珠单抗，一种抗白细胞介素-6受体抗体，用于治疗新型冠状病毒肺炎相关呼吸衰竭：一例病例报告。
Ann Oncol. 2020 Jul;31(7):961-964. doi: 10.1016/j.annonc.2020.03.300. Epub 2020 Apr 2.
Zotero 插件